Clovis Oncology partners with Qiagen on test

Qiagen will develop test to detect genetic mutation targeted by Clovis' cancer drug CO-1686

Associated Press

NEW YORK (AP) -- Diagnostic products maker Qiagen will develop a test that detects a genetic mutation targeted by Clovis Oncology's cancer drug CO-1686, the companies said Monday.

Clovis' experimental drug CO-1686 is designed to target two different genetic mutations in lung cancer. One mutation causes the cancer, and the other causes resistance to treatment with drugs like Tarceva and Iressa. Clovis expects to start using the Qiagen tests in expansion studies of CO-1686 that will begin later this year.

Clovis Oncology Inc. says CO-1686 could be used as a primary treatment or a secondary treatment for non-small cell lung cancer and as a secondary treatment in patients who are no longer being helped by their initial therapy. Clovis will continue development of its drug and Qiagen will be responsible for development of the test.

The companies did not disclose terms of the collaboration.

The Boulder, Colo., company's most advanced products include CO-1686 and breast and ovarian cancer drug rucaparib.

Clovis Oncology Inc. shares rose 72 cents to $51.30 Monday and were unchanged in late trading. Qiagen shares fell 6 cents to $20.96 during the day and gave up a penny to $20.95 after hours.

Rates

View Comments (0)